<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659461</url>
  </required_header>
  <id_info>
    <org_study_id>UKM-22</org_study_id>
    <nct_id>NCT03659461</nct_id>
  </id_info>
  <brief_title>Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus</brief_title>
  <acronym>GLP-1</acronym>
  <official_title>Comparative Study of Incretin System in Three Ethnic Groups With Abnormal Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity
      portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of
      DPPIV inhibitor in T2DM patients with different GLP-levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in blood glucose load response to sitagliptin</measure>
    <time_frame>pre-treatment of sitagliptin and post 12-week treatment of sitagliptin</time_frame>
    <description>change from blood glucose response at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in blood insulin response to sitagliptin</measure>
    <time_frame>pre-treatment of sitagliptin and post 12-week treatment of sitagliptin</time_frame>
    <description>change from blood insulin response at 12 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>low GLP-1 arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal GLP-1 arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are required to take oral 100mg Sitagliptin ( Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.</description>
    <arm_group_label>low GLP-1 arm</arm_group_label>
    <arm_group_label>normal GLP-1 arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are newly diagnosed of T2DM according to World Health Organisation criteria)
             and do not receive any glucose-lowering drugs

          -  Subjects with normal glucose tolerance test according to World Health Organisation
             criteria which is carried out immediately before inclusion in the study

          -  Subjects who are willing to participate and sign the informed consent form

        Exclusion Criteria:

          -  Patients with pre-existing T2DM

          -  Patients with family history of diabetes

          -  Patients receiving glucose-lowering medications

          -  Patients with anemia, abnormal serum creatinine level, macroalbuminuria, proliferative
             retinopathy, impaired liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamaruddin Nor Azmi</last_name>
    <role>Study Director</role>
    <affiliation>National University of Malaysia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shiau Chin Chong</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University of Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiau Chin Chong</last_name>
    <phone>+60163332983</phone>
    <email>shiauchin83@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kamaruddin Nor Azmi</last_name>
    <phone>+60391455555</phone>
    <email>norazmi@ppukm.ukm.edu.my</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <state>Johor</state>
        <zip>81100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chong Shiau Chin, MPHARM</last_name>
      <phone>+6073565000</phone>
      <email>shiauchin83@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone>+60361455555</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 2, 2018</last_update_submitted>
  <last_update_submitted_qc>September 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Chong Shiau Chin</investigator_full_name>
    <investigator_title>Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

